Рак желудка у больных молодого возраста. Литературный обзор

Рак желудка у больных молодого возраста. Литературный обзор

Автор: Пугаев Д.М., Любченко Л.Н., Рябов А.Б., Каприн А.Д.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 6 т.22, 2023 года.

Бесплатный доступ

Актуальность. Проблема заболеваемости раком желудка (РЖ) среди пациентов молодого возраста представляет собой значимую медико-социальную проблему. Частота РЖ у молодых пациентов составляет до 6 % от общего количества выявленных случаев этого новообразования. Материал и методы. Поиск источников производился в системах Medline, Elibrary. Включены данные как ретроспективных, так и проспективных клинических исследований. Обобщен опыт зарубежных и отечественных авторов Результаты. Прикладная значимость введенной молекулярно-генетической классификации РЖ состоит в формировании оценочных групп прогноза течения заболевания на основании мультифакториального анализа. Указанные классификации свидетельствуют о том, что местнораспространенный и первичной диссемированнный РЖ, диагностированный у больных молодого возраста, чаще всего обусловлен GS подтипом (TCGA) и MSS/EMT подтипом (ACRG) и характеризуется мутациями в генах CDH1, RhoА, CLDN18-ARHGAP . Данные изменения сопровождаются превалированием диффузного РЖ по классификации Lauren, язвенно-инфильтративным или диффузно-инфильтративным типом РЖ по классификации Borrmann (тип III и IV) с наличием аденокарциномы высокой степени злокачественности в комбинации с перстневидноклеточным компонентом.

Еще

Рак желудка у больных молодого возраста, молекулярная классификация, cdh1, rhoа, cldn18-arhgap

Короткий адрес: https://sciup.org/140303566

IDR: 140303566   |   DOI: 10.21294/1814-4861-2023-22-6-153-171

Список литературы Рак желудка у больных молодого возраста. Литературный обзор

  • Bollschweiler E., Berlth F., Baltin C., Mönig S., Hölscher A.H. Treatment of early gastric cancer in the Western World. World J Gastroenterol. 2014; 20(19): 5672-8. https://doi.org/10.3748/wjg.v20.i19.5672.
  • Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424. https://doi.org/10.3322/caac.21492.
  • Llanos O., Butte J.M., Crovari F., Duarte I., Guzmán S. Survival of young patients after gastrectomy for gastric cancer. World J Surg. 2006; 30(1): 17-20. https://doi.org/10.1007/s00268-005-7935-5.
  • Ang T.L., Fock K.M. Clinical epidemiology of gastric cancer. Singapore Med J. 2014; 55(12): 621-8. https://doi.org/10.11622/smedj.2014174.
  • Kang Y.K., Yook J.H., Park Y.K., Lee J.S., Kim Y.W., Kim J.Y., Ryu M.H., Rha S.Y., Chung I.J., Kim I.H., Oh S.C., Park Y.S., Son T., Jung M.R., Heo M.H., Kim H.K., Park C., Yoo C.H., Choi J.H., Zang D.Y., Jang Y.J., Sul J.Y., Kim J.G., Kim B.S., Beom S.H., Cho S.H., Ryu S.W., Kook M.C., Ryoo B.Y., Kim H.K., Yoo M.W., Lee N.S., Lee S.H., Kim G., Lee Y., Lee J.H., Noh S.H. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021; 39(26): 2903-13. https://doi.org/10.1200/JCO.20.02914.
  • Ji J., Shen L., Li Z., Zhang X., Liang H., Xue Y., Wang Y., Zhou Z., Yu J., Chen L., Du Y., Li G., Xiao G., Wu D., Zhou Y., Dang C., He Y., Zhang Z., Sun Y., Li Y. Perioperative Chemotherapy of Oxaliplatin Combined with S-1 (SOX) versus Postoperative Chemotherapy of SOX or Oxaliplatin with Capecitabine (XELOX) in Locally Advanced Gastric Adenocarcinoma with D2 Gastrectomy: a Randomized Phase III Trial (RESOLVE Trial). Ann Oncol 2019; 30(s5): 851-934. https://doi.org/10.1093/annonc/mdz394.033.
  • Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., Kopp H.G., Mayer F., Haag G.M., Luley K., Lindig U., Schmiegel W., Pohl M., Stoehlmacher J., Folprecht G., Probst S., Prasnikar N., Fischbach W., Mahlberg R., Trojan J., Koenigsmann M., Martens U.M., Thuss-Patience P., Egger M., Block A., Heinemann V., Illerhaus G., Moehler M., Schenk M., Kullmann F., Behringer D.M., Heike M., Pink D., Teschendorf C., Löhr C., Bernhard H., Schuch G., Rethwisch V., von Weikersthal L.F., Hartmann J.T., Kneba M., Daum S., Schulmann K., Weniger J., Belle S., Gaiser T., Oduncu F.S., Güntner M., Hozaeel W., Reichart A., Jäger E., Kraus T., Mönig S., Bechstein W.O., Schuler M., Schmalenberg H., Hofheinz R.D.; FLOT4-AIO Investigators. Perioperative chemotherapy with fuorouracil plus leucovorin, oxaliplatin, and docetaxel versus fuorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393(10184): 1948-57. https://doi.org/10.1016/S0140-6736(18)32557-1.
  • Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A., Furukawa H., Nakajima T., Ohashi Y., Imamura H., Higashino M., Yamamura Y., Kurita A., Arai K.; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fuoropyrimidine. N Engl J Med. 2007; 357(18): 1810-20. https://doi.org/10.1056/NEJMoa072252. Erratum in: N Engl J Med. 2008; 358(18): 1977.
  • Bang Y.J., Kim Y.W., Yang H.K., Chung H.C., Park Y.K., Lee K.H., Lee K.W., Kim Y.H., Noh S.I., Cho J.Y., Mok Y.J., Kim Y.H., Ji J., Yeh T.S., Button P., Sirzén F., Noh S.H.; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813): 315-21. https://doi.org/10.1016/S0140-6736(11)61873-4.
  • Yoshida K., Kodera Y., Kochi M., Ichikawa W., Kakeji Y., Sano T., Nagao N., Takahashi M., Takagane A., Watanabe T., Kaji M., Okitsu H., Nomura T., Matsui T., Yoshikawa T., Matsuyama J., Yamada M., Ito S., Takeuchi M., Fujii M. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efcacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019; 37(15): 1296-304. https://doi.org/10.1200/JCO.18.01138.
  • Kikuchi S., Kuroda S., Nishizaki M., Kagawa T., Kanzaki H., Kawahara Y., Kagawa S., Tanaka T., Okada H., Fujiwara T. Management of early gastric cancer that meet the indication for radical lymph node dissection following endoscopic resection: a retrospective cohort analysis. BMC Surg. 2017; 17(1): 72. https://doi.org/10.1186/s12893-017-0268-0.
  • Kitano S., Shiraishi N., Uyama I., Sugihara K., Tanigawa N.; Japanese Laparoscopic Surgery Study Group. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg. 2007; 245(1): 68-72. https://doi.org/10.1097/01.sla.0000225364.03133.f8.
  • Lee J.H., Yom C.K., Han H.S. Comparison of long-term outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer. Surg Endosc. 2009; 23(8): 1759-63. https://doi.org/10.1007/s00464-008-0198-0.
  • Seto Y., Shimoyama S., Kitayama J., Mafune K., Kaminishi M., Aikou T., Arai K., Ohta K., Nashimoto A., Honda I., Yamagishi H., Yamamura Y. Lymph node metastasis and preoperative diagnosis of depth of invasion in early gastric cancer. Gastric Cancer. 2001; 4(1): 34-8. https://doi.org/10.1007/s101200100014.
  • Kurihara N., Kubota T., Otani Y., Ohgami M., Kumai K., Sugiura H., Kitajima M. Lymph node metastasis of early gastric cancer with submucosal invasion. Br J Surg. 1998; 85(6): 835-9. https://doi.org/10.1046/j.1365-2168.1998.00743.x.
  • Gotoda T., Sasako M., Ono H., Katai H., Sano T., Shimoda T. Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br J Surg. 2001; 88(3): 444-9. https://doi.org/10.1046/j.1365-2168.2001.01725.x.
  • Sasako M., Sakuramoto S., Katai H., Kinoshita T., Furukawa H., Yamaguchi T., Nashimoto A., Fujii M., Nakajima T., Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011; 29(33): 4387-93. https://doi.org/10.1200/JCO.2011.36.5908.
  • Ramos-Santillan V., Friedmann P., Eskander M., Chuy J., Parides M., In H. The order of surgery and chemotherapy matters: Multimodality therapy and stage-specific differences in survival in gastric cancer. J Surg Oncol. 2023; 127(1): 56-65. https://doi.org/10.1002/jso.27110.
  • Shen L., Shan Y.S., Hu H.M., Price T.J., Sirohi B., Yeh K.H., Yang Y.H., Sano T., Yang H.K., Zhang X., Park S.R., Fujii M., Kang Y.K., Chen L.T. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013; 14(12): 535-47. https://doi.org/10.1016/S1470-2045(13)70436-4.
  • Lordick F., Siewert J.R. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer. 2005; 8(2): 78-85. https://doi.org/10.1007/s10120-005-0321-z.
  • Sun F., Sun H., Mo X., Tang J., Liao Y., Wang S., Su Y., Ma H. Increased survival rates in gastric cancer, with a narrowing gender gap and widening socioeconomic status gap: A period analysis from 1984 to 2013. J Gastroenterol Hepatol. 2018; 33(4): 837-46. https://doi.org/10.1111/jgh.14024.
  • Hsieh F.J., Wang Y.C., Hsu J.T., Liu K.H., Yeh C.N. Clinicopathological features and prognostic factors of gastric cancer patients aged 40 years or younger. J Surg Oncol. 2012; 105(3): 304-9. https://doi.org/10.1002/jso.22084.
  • Rona K.A., Schwameis K., Zehetner J., Samakar K., Green K., Samaan J., Sandhu K., Bildzukewicz N., Katkhouda N., Lipham J.C. Gastric cancer in the young: An advanced disease with poor prognostic features. J Surg Oncol. 2017; 115(4): 371-5. https://doi.org/10.1002/jso.24533.
  • Takatsu Y., Hiki N., Nunobe S., Ohashi M., Honda M., Yamaguchi T., Nakajima T., Sano T. Clinicopathological features of gastric cancer in young patients. Gastric Cancer. 2016; 19(2): 472-8. https://doi.org/10.1007/s10120-015-0484-1.
  • Chung H.W., Noh S.H., Lim J.B. Analysis of demographic characteristics in 3242 young age gastric cancer patients in Korea. World J Gastroenterol. 2010; 16(2): 256-63. https://doi.org/10.3748/wjg.v16.i2.256.
  • Kulig J., Popiela T., Kolodziejczyk P., Sierzega M., Jedrys J., Szczepanik A.M.; Polish Gastric Cancer Study Group. Clinicopathological profle and long-term outcome in young adults with gastric cancer: multicenter evaluation of 214 patients. Langenbecks Arch Surg. 2008; 393(1): 37-43. https://doi.org/10.1007/s00423-007-0208-z.
  • Koea J.B., Karpeh M.S., Brennan M.F. Gastric cancer in young patients: demographic, clinicopathological, and prognostic factors in 92 patients. Ann Surg Oncol. 2000; 7(5): 346-51. https://doi.org/10.1007/s10434-000 -0346-9.
  • Wu S.L., Zhang Y., Fu Y., Li J., Wang J.S. Gastric cancer incidence, mortality and burden in adolescents and young adults: a time-trend analysis and comparison among China, South Korea, Japan and the USA. BMJ Open. 2022; 12(7). https://doi.org/10.1136/bmjopen-2022-061038.
  • Lifshitz F., Lifshitz J.Z. Globesity: the root causes of the obesity epidemic in the USA and now worldwide. Pediatr Endocrinol Rev. 2014; 12(1): 17-34.
  • Medina-Franco H., Heslin M.J., Cortes-Gonzalez R. Clinicopathological characteristics of gastric carcinoma in young and elderly patients: a comparative study. Ann Surg Oncol. 2000; 7(7): 515-9. https://doi.org/10.1007/s10434-000-0515-x.
  • Cheng L., Chen S., Wu W., Kuo Z.C., Wei Z., Meng S., Chen C., Zhang C., He Y. Gastric cancer in young patients: a separate entity with aggressive features and poor prognosis. J Cancer Res Clin Oncol. 2020; 146(11): 2937-47. https://doi.org/10.1007/s00432-020-03268-w.
  • Puhr H.C., Karner A., Taghizadeh H., Jomrich G., Schoppmann S.F., Preusser M., Ilhan-Mutlu A. Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma. J Cancer Res Clin Oncol. 2020; 146(12): 3313-22. https://doi.org/10.1007/s00432-020-03302-x.
  • Huang Q., Zheng X., Jiao Y., Lei Y., Li X., Bi F., Guo F., Wang G., Liu M. A Distinct Clinicopathological Feature and Prognosis of Young Gastric Cancer Patients Aged ≤45 Years Old. Front Oncol. 2021; 11. https://doi.org/10.3389/fonc.2021.674224.
  • Zhou L., Jiang Z., Gu W., Han S. STROBE-clinical characteristics and prognosis factors of gastric cancer in young patients aged ≤30 years. Medicine (Baltimore). 2021; 100(26). https://doi.org/10.1097/MD.0000000000026336.
  • De B., Rhome R., Jairam V., Özbek U., Holcombe R.F., Buckstein M., Ang C. Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States. Gastric Cancer. 2018; 21(6): 889-99. https://doi.org/10.1007/s10120-018-0826-x.
  • Zhao B., Mei D., Lv W., Lu H., Bao S., Lin J., Huang B. Clinicopathologic Features, Survival Outcome, and Prognostic Factors in Gastric Cancer Patients 18-40 Years of Age. J Adolesc Young Adult Oncol. 2020; 9(4): 514-21. https://doi.org/10.1089/jayao.2019.0162.
  • McNeer G. Cancer of the stomach in the young. AJR. 1941; 45: 537-50.
  • Ushimaru Y., Kurokawa Y., Takahashi T., Saito T., Yamashita K., Tanaka K., Makino T., Yamasaki M., Nakajima K., Mori M., Doki Y. Is Laparoscopic Gastrectomy More Advantageous for Elderly Patients Than for Young Patients with Resectable Advanced Gastric Cancer? World J Surg. 2020; 44(7): 2332-9. https://doi.org/10.1007/s00268-020-05486-2.
  • Strong V.E., Russo A., Yoon S.S., Brennan M.F., Coit D.G., Zheng C.H., Li P., Huang C.M. Comparison of Young Patients with Gastric Cancer in the United States and China. Ann Surg Oncol. 2017; 24(13): 3964-71. https://doi.org/10.1245/s10434-017-6073-2.
  • Smith A.W., Bellizzi K.M., Keegan T.H., Zebrack B., Chen V.W., Neale A.V., Hamilton A.S., Shnorhavorian M., Lynch C.F. Health-related quality of life of adolescent and young adult patients with cancer in the United States: the Adolescent and Young Adult Health Outcomes and Patient Experience study. J Clin Oncol. 2013; 31(17): 2136-45. https://doi.org/10.1200/JCO.2012.47.3173.
  • Keegan T.H., Ries L.A., Barr R.D., Geiger A.M., Dahlke D.V., Pollock B.H., Bleyer W.A.; National Cancer Institute Next Steps for Adolescent and Young Adult Oncology Epidemiology Working Group. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer. 2016; 122(7): 1009-16. https://doi.org/10.1002/cncr.29869.
  • Parsons H.M., Harlan L.C., Lynch C.F., Hamilton A.S., Wu X.C., Kato I., Schwartz S.M., Smith A.W., Keel G., Keegan T.H. Impact of cancer on work and education among adolescent and young adult cancer survivors. J Clin Oncol. 2012; 30(19): 2393-400. https://doi.org/10.1200/JCO.2011.39.6333.
  • Dyussenbayev A. Age Periods of Human Life. Advances in Social Sciences Research Journal. 2017; 4(6). https://doi.org/10.14738/assrj.46.2924.
  • Henson D.E., Dittus C., Younes M., Nguyen H., Albores-Saavedra J. Diferential trends in the intestinal and difuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004; 128(7): 765-70. https://doi.org/10.5858/2004-128-765-DTITIA.
  • Wu-Williams A.H., Yu M.C., Mack T.M. Life-style, workplace, and stomach cancer by subsite in young men of Los Angeles County. Cancer Res. 1990; 50(9): 2569-76.
  • Song M., Choi J.Y., Yang J.J., Sung H., Lee Y., Lee H.W., Kong S.H., Lee H.J., Kim H.H., Kim S.G., Yang H.K., Kang D. Obesity at adolescence and gastric cancer risk. Cancer Causes Control. 2015; 26(2): 247-56. https://doi.org/10.1007/s10552-014-0506-z.
  • Banks M., Graham D., Jansen M., Gotoda T., Coda S., di Pietro M., Uedo N., Bhandari P., Pritchard D.M., Kuipers E.J., Rodriguez-Justo M., Novelli M.R., Ragunath K., Shepherd N., Dinis-Ribeiro M. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019; 68(9): 1545-75. https://doi.org/10.1136/gutjnl-2018-318126.
  • Yan Z.P., Xu T.T., An Z.T., Hu Y., Chen W.Z., Ma J.X. Efects of Jianpi Yiqi formula on expression of PI3K-Akt signaling pathway in gastric tissue of rats with chronic atrophic gastritis. J Trad Chin Med Pharm. 2019; 34(10): 4800-4.
  • Lahner E., Conti L., Annibale B., Corleto V.D. Current Perspectives in Atrophic Gastritis. Curr Gastroenterol Rep. 2020; 22(8): 38. https://doi.org/10.1007/s11894-020-00775-1.
  • Ajani J.A., Lee J., Sano T., Janjigian Y.Y., Fan D., Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017; 3. https://doi.org/10.1038/nrdp.2017.36.
  • Moss S.F. The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. Cell Mol Gastroenterol Hepatol. 2016; 3(2): 183-91. https://doi.org/10.1016/j.jcmgh.2016.12.001.
  • Correa P., Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007; 133(2): 659-72. https://doi.org/10.1053/j.gastro.2007.06.026.
  • Pisanu A., Podda M., Cois A., Uccheddu A. Gastric cancer in the young: is it a diferent clinical entity? A retrospective cohort study. Gastroenterol Res Pract. https://doi.org/10.1155/2014/125038.
  • Koshida Y., Koizumi W., Sasabe M., Katoh Y., Okayasu I. Association of Helicobacter pylori-dependent gastritis with gastric carcinomas in young Japanese patients: histopathological comparison of difuse and intestinal type cancer cases. Histopathology. 2000; 37(2): 124-30. https://doi.org/10.1046/j.1365-2559.2000.00948.x.
  • Hirahashi M., Yao T., Matsumoto T., Nishiyama K., Oya M., Iida M., Tsuneyoshi M. Intramucosal gastric adenocarcinoma of poorly diferentiated type in the young is characterized by Helicobacter pylori infection and antral lymphoid hyperplasia. Mod Pathol. 2007; 20(1): 29-34. https://doi.org/10.1038/modpathol.3800714.
  • Kono Y., Kanzaki H., Tsuzuki T., Takatani M., Nasu J., Kawai D., Takenaka R., Tanaka T., Iwamuro M., Kawano S., Kawahara Y., Fujiwara T., Okada H. A multicenter observational study on the clinicopathological features of gastric cancer in young patients. J Gastroenterol. 2019; 54(5): 419-26. https://doi.org/10.1007/s00535-018-1525-4.
  • Tatemichi M., Sasazuki S., Inoue M., Tsugane S.; Japan Public Health Center Study Group. Diferent etiological role of Helicobacter pylori (Hp) infection in carcinogenesis between differentiated and undiferentiated gastric cancers: a nested case-control study using IgG titer against Hp surface antigen. Acta Oncol. 2008; 47(3): 360-5. https://doi.org/10.1080/02841860701843035.
  • Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan.
  • Peleteiro B., Bastos A., Ferro A., Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci. 2014; 59(8): 1698-709. https://doi.org/10.1007/s10620-014-3063-0. Erratum in: Dig Dis Sci. 2015; 60(9): 2849.
  • Song H., Ekheden I.G., Zheng Z., Ericsson J., Nyrén O., Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015; 351. https://doi.org/10.1136/bmj.h3867. Erratum in: BMJ. 2015; 351.
  • Chen J.N., He D., Tang F., Shao C.K. Epstein-Barr virus-associated gastric carcinoma: a newly defned entity. J Clin Gastroenterol. 2012; 46(4): 262-71. https://doi.org/10.1097/MCG.0b013e318249c4b8.
  • Moore A., Hikri E., Goshen-Lago T., Barkan T., Morgenstern S., Brook E., Maderer A., Roth W., Gordon N., Kashtan H., Brenner B., Moehler M., Aharon I.B. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis? BMC Cancer. 2020; 20(1): 34. https://doi.org/10.1186/s12885-020-6517-0.
  • Oliveira C., Pinheiro H., Figueiredo J., Seruca R., Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015; 16(2): 60-70. https://doi.org/10.1016/S1470-2045(14)71016-2.
  • Worthley D.L., Phillips K.D., Wayte N., Schrader K.A., Healey S., Kaurah P., Shulkes A., Grimpen F., Clouston A., Moore D., Cullen D., Ormonde D., Mounkley D., Wen X., Lindor N., Carneiro F., Huntsman D.G., Chenevix-Trench G., Suthers G.K. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012; 61(5): 774-9. https://doi.org/10.1136/gutjnl-2011-300348. Erratum in: Gut. 2012; 61(9): 1305.
  • Caldas C., Carneiro F., Lynch H.T., Yokota J., Wiesner G.L., Powell S.M., Lewis F.R., Huntsman D.G., Pharoah P.D., Jankowski J.A., MacLeod P., Vogelsang H., Keller G., Park K.G., Richards F.M., Maher E.R., Gayther S.A., Oliveira C., Grehan N., Wight D., Seruca R., Roviello F., Ponder B.A., Jackson C.E. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999; 36(12): 873-80.
  • Hansford S., Kaurah P., Li-Chang H., Woo M., Senz J., Pinheiro H., Schrader K.A., Schaeffer D.F., Shumansky K., Zogopoulos G., Santos T.A., Claro I., Carvalho J., Nielsen C., Padilla S., Lum A., Talhouk A., BakerLange K., Richardson S., Lewis I., Lindor N.M., Pennell E., MacMillan A., Fernandez B., Keller G., Lynch H., Shah S.P., Guilford P., Gallinger S., Corso G., Roviello F., Caldas C., Oliveira C., Pharoah P.D., Huntsman D.G. Hereditary Difuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015; 1(1): 23-32. https://doi.org/10.1001/jamaoncol.2014.168. Erratum in: JAMA Oncol. 2015; 1(1): 110.
  • Pharoah P.D., Guilford P., Caldas C.; International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers frgast.2001.29611.
  • Kaurah P., MacMillan A., Boyd N., Senz J., De Luca A., Chun N., Suriano G., Zaor S., Van Manen L., Gilpin C., Nikkel S., ConnollyWilson M., Weissman S., Rubinstein W.S., Sebold C., Greenstein R., Stroop J., Yim D., Panzini B., McKinnon W., Greenblatt M., Wirtzfeld D., Fontaine D., Coit D., Yoon S., Chung D., Lauwers G., Pizzuti A., Vaccaro C., Redal M.A., Oliveira C., Tischkowitz M., Olschwang S., Gallinger S., Lynch H., Green J., Ford J., Pharoah P., Fernandez B., Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary difuse gastric cancer. JAMA. 2007; 297(21): 2360-72. https://doi.org/10.1001/jama.297.21.2360.
  • Pandalai P.K., Lauwers G.Y., Chung D.C., Patel D., Yoon S.S. Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery. 2011; 149(3): 347-55. https://doi.org/10.1016/j.surg.2010.07.005.
  • Fitzgerald R.C., Hardwick R., Huntsman D., Carneiro F., Guilford P., Blair V., Chung D.C., Norton J., Ragunath K., Van Krieken J.H., Dwerryhouse S., Caldas C.; International Gastric Cancer Linkage Consortium. Hereditary difuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010; 47(7): 436-44. https://doi.org/10.1136/jmg.2009.074237. Erratum in: J Med Genet. 2011; 48(3): 216. Van Krieken, Nicola [corrected to Van Grieken, Nicola C].
  • Oliveira C., Seruca R., Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol. 2006; 14(1): 21-33. https://doi.org/10.1177/106689690601400105.
  • Yamamoto E., Suzuki H., Takamaru H., Yamamoto H., Toyota M., Shinomura Y. Role of DNA methylation in the development of difuse-type gastric cancer. Digestion. 2011; 83(4): 241-9. https://doi.org/10.1159/000320453.
  • Blair V.R., McLeod M., Carneiro F., Coit D.G., D’Addario J.L., van Dieren J.M., Harris K.L., Hoogerbrugge N., Oliveira C., van der Post R.S., Arnold J., Benusiglio P.R., Bisseling T.M., Boussioutas A., Cats A., Charlton A., Schreiber K.E.C., Davis J.L., Pietro M.D., Fitzgerald R.C., Ford J.M., Gamet K., Gullo I., Hardwick R.H., Huntsman D.G., Kaurah P., Kupfer S.S., Latchford A., Mansfeld P.F., Nakajima T., Parry S., Rossaak J., Sugimura H., Svrcek M., Tischkowitz M., Ushijima T., Yamada H., Yang H.K., Claydon A., Figueiredo J., Paringatai K., Seruca R., Bougen-Zhukov N., Brew T., Busija S., Carneiro P., DeGregorio L., Fisher H., Gardner E., Godwin T.D., Holm K.N., Humar B., Lintott C.J., Monroe E.C., Muller M.D., Norero E., Nouri Y., Paredes J., Sanches J.M., Schulpen E., Ribeiro A.S., Sporle A., Whitworth J., Zhang L., Reeve A.E., Guilford P. Hereditary difuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020; 21(8): 386-97. https://doi.org/10.1016/S1470-2045(20)30219-9.
  • van der Post R.S., Vogelaar I.P., Carneiro F., Guilford P., Huntsman D., Hoogerbrugge N., Caldas C., Schreiber K.E., Hardwick R.H., Ausems M.G., Bardram L., Benusiglio P.R., Bisseling T.M., Blair V., Bleiker E., Boussioutas A., Cats A., Coit D., DeGregorio L., Figueiredo J., Ford J.M., Heijkoop E., Hermens R., Humar B., Kaurah P., Keller G., Lai J., Ligtenberg M.J., O’Donovan M., Oliveira C., Pinheiro H., Ragunath K., Rasenberg E., Richardson S., Roviello F., Schackert H., Seruca R., Taylor A., Ter Huurne A., Tischkowitz M., Joe S.T., van Dijck B., van Grieken N.C., van Hillegersberg R., van Sandick J.W., Vehof R., van Krieken J.H., Fitzgerald R.C. Hereditary difuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015; 52(6): 361-74. https://doi.org/10.1136/jmedgenet-2015-103094.
  • Yanaru-Fujisawa R., Nakamura S., Moriyama T., Esaki M., Tsuchigame T., Gushima M., Hirahashi M., Nagai E., Matsumoto T., Kitazono T. Familial fundic gland polyposis with gastric cancer. Gut. 2012; 61(7): 1103-4. https://doi.org/10.1136/gutjnl-2011-301384.
  • Worthley D.L., Phillips K.D., Wayte N., Schrader K.A., Healey S., Kaurah P., Shulkes A., Grimpen F., Clouston A., Moore D., Cullen D., Ormonde D., Mounkley D., Wen X., Lindor N., Carneiro F., Huntsman D.G., Chenevix-Trench G., Suthers G.K. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012; 61(5): 774-9. https://doi.org/10.1136/gutjnl-2011-300348. Erratum in: Gut. 2012; 61(9): 1305.
  • Corso G., Roncalli F., Marrelli D., Carneiro F., Roviello F. History, pathogenesis, and management of familial gastric cancer: original study of John XXIII’s family. Biomed Res Int. 2013. https://doi.org/10.1155/2013/385132.
  • Howe J.R., Mitros F.A., Summers R.W. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol. 1998; 5(8): 751-6. https://doi.org/10.1007/BF02303487.
  • van Lier M.G., Westerman A.M., Wagner A., Looman C.W., Wilson J.H., de Rooij F.W., Lemmens V.E., Kuipers E.J., Mathus-Vliegen E.M., van Leerdam M.E. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut. 2011; 60(2): 141-7. https://doi.org/10.1136/gut.2010.223750.
  • Masciari S., Dewanwala A., Stoffel E.M., Lauwers G.Y., Zheng H., Achatz M.I., Riegert-Johnson D., Foretova L., Silva E.M., Digianni L., Verselis S.J., Schneider K., Li F.P., Fraumeni J., Garber J.E., Syngal S. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med. 2011; 13(7): 651-7. https://doi.org/10.1097/GIM.0b013e31821628b6.
  • Rahner N., Steinke V., Schlegelberger B., Eisinger F., Hutter P., Olschwang S. Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012. Eur J Hum Genet. 2013; 21(1). https://doi.org/10.1038/ejhg.2012.164.
  • Capelle L.G., Van Grieken N.C., Lingsma H.F., Steyerberg E.W., Klokman W.J., Bruno M.J., Vasen H.F., Kuipers E.J. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 2010; 138(2): 487-92. https://doi.org/10.1053/j.gastro.2009.10.051.
  • Malkin D., Li F.P., Strong L.C., Fraumeni J.F., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985): 1233-8. https://doi.org/10.1126/science.1978757. Erratum in: Science. 1993; 259(5097): 878.
  • Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002; 19(6): 607-14. https://doi.org/10.1002/humu.10081.
  • Masciari S., Dewanwala A., Stoffel E.M., Lauwers G.Y., Zheng H., Achatz M.I., Riegert-Johnson D., Foretova L., Silva E.M., Digianni L., Verselis S.J., Schneider K., Li F.P., Fraumeni J., Garber J.E., Syngal S. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med. 2011; 13(7): 651-7. https://doi.org/10.1097/GIM.0b013e31821628b6.
  • Lipton L., Tomlinson I. The genetics of FAP and FAP-like syndromes. Fam Cancer. 2006; 5(3): 221-6. https://doi.org/10.1007/s10689-005-5673-3.
  • Vasen H.F., Möslein G., Alonso A., Aretz S., Bernstein I., Bertario L., Blanco I., Bülow S., Burn J., Capella G., Colas C., Engel C., Frayling I., Friedl W., Hes F.J., Hodgson S., Järvinen H., Mecklin J.P., Møller P., Myrhøi T., Nagengast F.M., Parc Y., Phillips R., Clark S.K., de Leon M.P., Renkonen-Sinisalo L., Sampson J.R., Stormorken A., Tejpar S., Thomas H.J., Wijnen J. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008; 57(5): 704-13. https://doi.org/10.1136/gut.2007.136127.
  • Utsunomiya J., Gocho H., Miyanaga T., Hamaguchi E., Kashimure A. Peutz-Jeghers syndrome: its natural course and management. Johns Hopkins Med J. 1975; 136(2): 71-82.
  • van Lier M.G., Wagner A., Mathus-Vliegen E.M., Kuipers E.J., Steyerberg E.W., van Leerdam M.E. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010; 105(6): 1258-64. https://doi.org/10.1038/ajg.2009.725.
  • Allen B.A., Terdiman J.P. Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. Best Pract Res Clin Gastroenterol. 2003; 17(2): 237-58. https://doi.org/10.1016/s1521-6918(02)00149-x.
  • Zhou F., Xu Y., Shi J., Lan X., Zou X., Wang L., Huang Q. Expression profle of E-cadherin, estrogen receptors, and P53 in early-onset gastric cancers. Cancer Med. 2016; 5(12): 3403-11. https://doi.org/10.1002/cam4.931.
  • Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517): 202-9. https://doi.org/10.1038/nature13480.
  • Cristescu R., Lee J., Nebozhyn M., Kim K.M., Ting J.C., Wong S.S., Liu J., Yue Y.G., Wang J., Yu K., Ye X.S., Do I.G., Liu S., Gong L., Fu J., Jin J.G., Choi M.G., Sohn T.S., Lee J.H., Bae J.M., Kim S.T., Park S.H., Sohn I., Jung S.H., Tan P., Chen R., Hardwick J., Kang W.K., Ayers M., Hongyue D., Reinhard C., Loboda A., Kim S., Aggarwal A. Molecular analysis of gastric cancer identifes subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5): 449-56. https://doi.org/10.1038/nm.3850.
  • Danishevich A.M., Pospehova N.I., Stroganova A.M., Golovina D.A., Nikulin M.P., Kalinin A.E., Nikolaev S.E., Stilidi I.S., Lyubchenko L.N. [Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer]. Mol Biol (Mosk). 2023; 57(1): 71-84. (in Russian). https://doi.org/10.31857/S0026898423010044.
  • Shimada H., Noie T., Ohashi M., Oba K., Takahashi Y. Clinical signifcance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014; 17(1): 26-33. https://doi.org/10.1007/s10120-013-0259-5.
  • Marrelli D., Pinto E., De Stefano A., Farnetani M., Garosi L., Roviello F. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001; 181(1): 16-9. https://doi.org/10.1016/s0002-9610(00)00549-3.
  • Song Y.X., Huang X.Z., Gao P., Sun J.X., Chen X.W., Yang Y.C., Zhang C., Liu H.P., Wang H.C., Wang Z.N. Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis. Dis Markers. 2015. https://doi.org/10.1155/2015/549843.
  • Kono K., Amemiya H., Sekikawa T., Iizuka H., Takahashi A., Fujii H., Matsumoto Y. Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg. 2002; 19(5): 359-65. https://doi.org/10.1159/000065838.
  • Matsuoka T., Yashiro M. The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel). 2014; 6(3): 1441-63. https://doi.org/10.3390/cancers6031441.
  • Lee H.E., Kim M.A., Lee H.S., Jung E.J., Yang H.K., Lee B.L., Bang Y.J., Kim W.H. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012; 107(2): 325-33. https://doi.org/10.1038/bjc.2012.237.
  • Oki E., Zhao Y., Yoshida R., Egashira A., Ohgaki K., Morita M., Kakeji Y., Maehara Y. The diference in p53 mutations between cancers of the upper and lower gastrointestinal tract. Digestion. 2009; 79s1: 33-9. https://doi.org/10.1159/000167864.
  • Park S., Lee J., Kim Y.H., Park J., Shin J.W., Nam S. Clinical Relevance and Molecular Phenotypes in Gastric Cancer, of TP53 Mutations and Gene Expressions, in Combination With Other Gene Mutations. Sci Rep. 2016; 6. https://doi.org/10.1038/srep34822.
  • Amé J.C., Spenlehauer C., de Murcia G. The PARP superfamily. Bioessays. 2004; 26(8): 882-93. https://doi.org/10.1002/bies.20085.
  • D’Amours D., Desnoyers S., D’Silva I., Poirier G.G. Poly(ADPribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999; 342: 249-68.
  • Zhang Q.W., Liu L., Chen R., Wei Y.Q., Li P., Shi H.S., Zhao Y.W. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a metaanalysis. Asian Pac J Cancer Prev. 2012; 13(6): 2903-8. https://doi.org/10.7314/apjcp.2012.13.6.2903.
  • An J.Y., Baik Y.H., Choi M.G., Noh J.H., Sohn T.S., Kim S. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: analysis of a single institutional experience. Ann Surg. 2007; 246(5): 749-53. https://doi.org/10.1097/SLA.0b013e31811f3fb7.
  • Roviello F., Rossi S., Marrelli D., Pedrazzani C., Corso G., Vindigni C., Morgagni P., Saragoni L., de Manzoni G., Tomezzoli A. Number of lymph node metastases and its prognostic signifcance in early gastric cancer: a multicenter Italian study. J Surg Oncol. 2006; 94(4): 275-80; discussion 274. https://doi.org/10.1002/jso.20566.
  • Ji T., Zhou F., Wang J., Zi L. Risk factors for lymph node metastasis of early gastric cancers in patients younger than 40. Medicine (Baltimore). 2017; 96(37). https://doi.org/10.1097/MD.0000000000007874.
  • Smith D.D., Schwarz R.R., Schwarz R.E. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005; 23(28): 7114-24. https://doi.org/10.1200/JCO.2005.14.621.
  • Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023; 26(1): 1-25. https://doi.org/10.1007/s10120-022-01331-8.
  • Petrillo A., Pompella L., Tirino G., Pappalardo A., Laterza M.M., Caterino M., Orditura M., Ciardiello F., Lieto E., Galizia G., Castoro C., De Vita F. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers (Basel). 2019; 11(3): 399. https://doi.org/10.3390/cancers11030399.
  • Al-Batran S.E., Homann N., Schmalenberg H., Kopp H.G., Haag G.M., Luley K.B., Schmiegel W.H., Folprecht G., Probst S., Prasnikar N., Thuss-Patience P.C., Fischbach W., Trojan J., Koenigsmann M., Pauligk C., Goetze T.O., Jaeger E., Meiler J., Schuler M.H., Hofheinz R. Perioperative chemotherapy with docetaxel, oxaliplatin, and fuorouracil/ leucovorin (FLOT) versus epirubicin, cisplatin, and fuorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J. Clin. Oncol. 2017; 35(s15).
  • Al-Batran S.E., Pauligk C., Homann N., Schmalenberg H., Kopp H., Haag G.M., Luley K., Folprecht G., Probst S., Thuss-Patience P., Trojan J., Koenigsmann M., Lindig U., Pohl M., Kasper S., Möhler M., Goetze T., Schuler M., Jaeger E., Hofheinz R.D. Docetaxel, oxaliplatin, and fuorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Ann. Oncol. 2017; 28s5. https://doi.org/10.1093/annonc/mdx440.019.
  • Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Rüschoff J., Kang Y.K.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742): 687-97. https://doi.org/10.1016/S0140-6736(10)61121-X. Erratum in: Lancet. 2010; 376(9749): 1302.
  • Kim W.H., Gomez-Izquierdo L., Vilardell F., Chu K.M., Soucy G., Dos Santos L.V., Monges G., Viale G., Brito M.J., Osborne S., Noé J., Du X. HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study. Appl Immunohistochem Mol Morphol. 2018; 26(4): 239-45. https://doi.org/10.1097/PAI.0000000000000423.
  • Fuchs C.S., https://doi.org/T., Jang R.W., Muro K., Satoh T., Machado M., Sun W., Jalal S.I., Shah M.A., Metges J.P., Garrido M., Golan T., Mandala M., Wainberg Z.A., Catenacci D.V., Ohtsu A., Shitara K., Geva R., Bleeker J., Ko A.H., Ku G., Philip P., Enzinger P.C., Bang Y.J., Levitan D., Wang J., Rosales M., Dalal R.P., Yoon H.H. Safety and Efcacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018; 4(5). https://doi.org/10.1001/jamaoncol.2018.0013. Erratum in: JAMA Oncol. 2019; 5(4): 579.
  • Thomassen I., van Gestel Y.R., van Ramshorst B., Luyer M.D., Bosscha K., Nienhuijs S.W., Lemmens V.E., de Hingh I.H. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014; 134(3): 622-8. https://doi.org/10.1002/ ijc.28373.
  • Issels R.D. Hyperthermia adds to chemotherapy. Eur J Cancer. 2008; 44(17): 2546-54. https://doi.org/10.1016/j.ejca.2008.07.038.
  • Van der Speeten K., Stuart O.A., Sugarbaker P.H. Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol. 2009; 6(1): 72-81. https://doi.org/10.2174/157016309787581084.
  • Yan T.D., Deraco M., Baratti D., Kusamura S., Elias D., Glehen O., Gilly F.N., Levine E.A., Shen P., Mohamed F., Moran B.J., Morris D.L., Chua T.C., Piso P., Sugarbaker P.H. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27(36): 6237-42. https://doi.org/10.1200/JCO.2009.23.9640.
  • Chua T.C., Moran B.J., Sugarbaker P.H., Levine E.A., Glehen O., Gilly F.N., Baratti D., Deraco M., Elias D., Sardi A., Liauw W., Yan T.D., Barrios P., Gómez Portilla A., de Hingh I.H., Ceelen W.P., Pelz J.O., Piso P., González-Moreno S., Van Der Speeten K., Morris D.L. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012; 30(20): 2449-56. https://doi.org/10.1200/JCO.2011.39.7166.
  • Verwaal V.J., van Ruth S., de Bree E., van Sloothen G.W., van Tinteren H., Boot H., Zoetmulder F.A. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21(20): 3737-43. https://doi.org/10.1200/JCO.2003.04.187.
  • Koga S., Hamazoe R., Maeta M., Shimizu N., Murakami A., Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer. 1988; 61(2): 232-7. https://doi.org/10.1002/1097-0142(19880115)61:23.0.co;2-u.
  • Yarema R., Mielko J., Fetsych T., Ohorchak M., Skorzewska M., Rawicz-Pruszyński K., Mashukov A., Maksimovsky V., Jastrzębski T., Polkowski W., Gyrya P., Kovalchuk Y., Safyan V., Karelin I., Kopetskiy V., Kolesnik O., Kondratskiy Y., Paskonis M. Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: A retrospective cooperative Central-Eastern European study. Cancer Med. 2019; 8(6): 2877-85. https://doi.org/10.1002/cam4.2204.
  • Beeharry M.K., Zhu Z.L., Liu W.T., Yao X.X., Yan M., Zhu Z.G. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer. 2019; 19(1): 932. https://doi.org/10.1186/s12885-019-6125-z. Erratum in: BMC Cancer. 2019; 19(1): 1256.
  • Reutovich M.Y., Krasko O.V., Sukonko O.G. Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review. J Gastrointest Oncol. 2021; 12(s1): 5-17. https://doi.org/10.21037/jgo-20-129.
  • Fujimoto S., Shrestha R.D., Kokubun M., Ohta M., Takahashi M., Kobayashi K., Kiuchi S., Okui K., Miyoshi T., Arimizu N., Takamizawa H. Intraperitoneal hyperthermic perfusion combined with surgery efective for gastric cancer patients with peritoneal seeding. Ann Surg. 1988; 208(1): 36-41. https://doi.org/10.1097/00000658-198807000-00005.
  • Prabhu A., Mishra D., Brandl A., Yonemura Y. Gastric Cancer With Peritoneal Metastasis-A Comprehensive Review of Current Intraperitoneal Treatment Modalities. Front Oncol. 2022; 12. https://doi.org/10.3389/fonc.2022.864647.
  • Chia C.S., You B., Decullier E., Vaudoyer D., Lorimier G., Abboud K., Bereder J.M., Arvieux C., Boschetti G., Glehen O.; BIG RENAPE Group. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Ann Surg Oncol. 2016; 23(6): 1971-9. https://doi.org/10.1245/s10434-015-5081-3.
  • Yonemura Y., Fujimura T., Nishimura G., Falla R., Sawa T., Katayama K., Tsugawa K., Fushida S., Miyazaki I., Tanaka M., Endou Y., Sasaki T. Efects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery. 1996; 119(4): 437-44. https://doi.org/10.1016/s0039-6060(96)80145-0.
  • Glehen O., Schreiber V., Cotte E., Sayag-Beaujard A.C., Osinsky D., Freyer G., François Y., Vignal J., Gilly F.N. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004; 139(1): 20-6. https://doi.org/10.1001/archsurg.139.1.20.
  • Hall J.J., Loggie B.W., Shen P., Beamer S., Douglas Case L., McQuellon R., Geisinger K.R., Levine E.A. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg. 2004; 8(4): 454-63. https://doi.org/10.1016/j.gassur.2003.12.014.
  • Bonnot P.E., Piessen G., Kepenekian V., Decullier E., Pocard M., Meunier B., Bereder J.M., Abboud K., Marchal F., Quenet F., Goere D., Msika S., Arvieux C., Pirro N., Wernert R., Rat P., Gagnière J., Lefevre J.H., Courvoisier T., Kianmanesh R., Vaudoyer D., Rivoire M., Meeus P., Passot G., Glehen O.; FREGAT and BIG-RENAPE Networks. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTOCHIP study): A Propensity Score Analysis. J Clin Oncol. 2019; 37(23): 2028-40. https://doi.org/10.1200/JCO.18.01688.
  • Rau B., Brandl A., Piso P., Pelz J., Busch P., Demtröder C., Schüle S., Schlitt H.J., Roitman M., Tepel J., Sulkowski U., Uzunoglu F., Hünerbein M., Hörbelt R., Ströhlein M., Beckert S., Königsrainer I., Königsrainer A.; Peritoneum Surface Oncology Group and members of the StuDoQ|Peritoneum Registry of the German Society for General and Visceral Surgery (DGAV). Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020; 23(1): 11-22. https://doi.org/10.1007/s10120-019-00978-0.
  • Alberto M., Brandl A., Garg P.K., Gül-Klein S., Dahlmann M., Stein U., Rau B. Pressurized intraperitoneal aerosol chemotherapy and its efect on gastric-cancer-derived peritoneal metastases: an overview. Clin Exp Metastasis. 2019; 36(1): 1-14. https://doi.org/10.1007/s10585-019-09955-4.
  • Solass W., Kerb R., Mürdter T., Giger-Pabst U., Strumberg D., Tempfer C., Zieren J., Schwab M., Reymond M.A. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: frst evidence for efcacy. Ann Surg Oncol. 2014; 21(2): 553-9. https://doi.org/10.1245/s10434-013-3213-1.
  • Alyami M., Gagniere J., Sgarbura O., Cabelguenne D., Villeneuve L., Pezet D., Quenet F., Glehen O., Bakrin N., Passot G. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017; 43(11): 2178-83. https://doi.org/10.1016/j.ejso.2017.09.010.
  • Di Giorgio A., Schena C.A., El Halabieh M.A., Abatini C., Vita E., Strippoli A., Inzani F., Rodolfno E., Romanò B., Pacelli F., Rotolo S. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol. 2020; 34: 270-5. https://doi.org/10.1016/j.suronc.2020.05.006.
  • Khomyakov V.M., Ryabov A.B., Kolobaev I.V., Bolotina L.V., Utkina A.B., Sobolev D.D., Kuznetsova O.S., Kaprin A.D. Vnutribryushnaya aerozol'naya khimioterapiya pod davleniem v sochetanii s sistemnoi khimioterapiei - novyi podkhod v lechenii bol'nykh rakom zheludka s peritoneal'nym kartsinomatozom. Sibirskii onkologicheskii zhurnal. 2020; 19(4): 49-58. https://doi.org/10.21294/1814-4861-2020-19-4-49-58.
  • Chung H.C., Bang Y.J., Fuchs C., Qin S.K., Satoh T., Shitara K., Tabernero J., Van Cutsem E., Alsina M., Cao Z.A., Lu J., Bhagia P., Shih C.S., Janjigian Y.Y. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE811. Future Oncol. 2021; 17(5): 491-501. https://doi.org/10.2217/fon-2020-0737.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp